Neuromyelitis Optica (CNP-Aquaporin 4)

COUR’s CNP-Aquaporin-4 is designed to address the fundamental mechanisms that drive NMO disease symptoms by reprogramming the immune system to tolerate the self-antigens associated with NMO. Our breakthrough technology will provide long-term therapeutic benefit without causing immune suppressive side-effects.